Edwards Lifesciences (EW) total liabilities
Edwards Lifesciences (EW) had total liabilities of $3.36B at the end of fiscal 2025 (December 31, 2025). That is 12.3% higher than the $2.99B of fiscal 2024. Figures as of 18 Nov 2026, 18:54 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Total liabilities, fiscal 2025
- $3.36B
- Change on fiscal 2024
- +12.3%
- Growth, 5 years
- +4.8% a year
- Highest on record
- $3.36Bfiscal 2025
- Lowest on record
- $2.49Bfiscal 2022
- Fiscal years on record
- 62020–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Edwards Lifesciences total liabilities, in more detail
Over the five fiscal years to 2025 total liabilities grew at a compound 4.8% a year. Across the 6 fiscal years on record (2020–2025), the highest was $3.36B in fiscal 2025 and the lowest $2.49B in fiscal 2022.
Total liabilities by fiscal year
Edwards Lifesciences total liabilities, year by year
| Fiscal year | Total liabilities | Change | Year ended |
|---|---|---|---|
| 2025 | $3.36B | 12.3% up | |
| 2024 | $2.99B | 13.2% up | |
| 2023 | $2.64B | 6.4% up | |
| 2022 | $2.49B | 6.8% down | |
| 2021 | $2.67B | 0.1% up | |
| 2020 | $2.66B | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.
How to read it
It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.
Total liabilities at health care companies of similar size
| Company | Total liabilities | Fiscal year |
|---|---|---|
| Boston Scientific BSX | $19.20B | 2025 |
| Cardinal Health CAH | $60.02B | 2026 |
| argenx ARGX | $1.36B | 2025 |
| Edwards Lifesciences EW | $3.36B | 2025 |
| Becton, Dickinson BDX | $29.94B | 2025 |
| IDEXX Laboratories IDXX | $1.75B | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Edwards Lifesciences, figure by figure
- Edwards Lifesciences market cap
- Edwards Lifesciences revenue
- Edwards Lifesciences earnings
- Edwards Lifesciences earnings per share (EPS)
- Edwards Lifesciences P/E ratio
- Edwards Lifesciences P/S ratio
- Edwards Lifesciences P/B ratio
- Edwards Lifesciences free cash flow
- Edwards Lifesciences operating margin
- Edwards Lifesciences dividend
- Edwards Lifesciences shares outstanding
- Edwards Lifesciences total debt
- Edwards Lifesciences cash on hand
- Edwards Lifesciences total assets
- Edwards Lifesciences net assets (shareholders' equity)
- Edwards Lifesciences return on equity (ROE)
- Edwards Lifesciences return on invested capital (ROIC)
Edwards Lifesciences (EW) overview: price, valuation and scorecardAll health care companies by market value
Edwards Lifesciences total liabilities: questions and answers
How large are Edwards Lifesciences's total liabilities?
Edwards Lifesciences (EW) had total liabilities of $3.36B at the end of fiscal 2025 (December 31, 2025). That is 12.3% higher than the $2.99B of fiscal 2024.
What is the growth rate of Edwards Lifesciences's total liabilities?
Over the five fiscal years to 2025 total liabilities grew at a compound 4.8% a year.
What are the highest and lowest total liabilities figures on record for Edwards Lifesciences?
Across the 6 fiscal years on record (2020–2025), the highest was $3.36B in fiscal 2025 and the lowest $2.49B in fiscal 2022.
How is Edwards Lifesciences's total liabilities calculated?
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Edwards Lifesciences it is on record here for 6 fiscal years, 2020 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: total liabilities
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Edwards Lifesciences (EW) total liabilities”, data as of 18 November 2026. https://funkfolio.com/stock/EW/total-liabilities
Underlying data: the company's filings with the SEC and Yahoo Finance.